Status:
COMPLETED
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
Lead Sponsor:
Amgen
Conditions:
Postmenopausal Osteoporosis
Eligibility:
FEMALE
50-70 years
Phase:
PHASE2
Brief Summary
This study is structured to estimate the effect of denosumab, compared to placebo and alendronate, on several bone parameters.
Eligibility Criteria
Inclusion
- Key
- Postmenopausal, ambulatory women between 50 and 70 years old who are generally in good health.
- Must have low bone mineral density and meet specific eligibility criteria.
- Key
Exclusion
- Subjects must not currently be receiving any medication that affects bone metabolism or have an underlying condition that affects their ability to take alendronate or receive denosumab.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
247 Patients enrolled
Trial Details
Trial ID
NCT00293813
Start Date
May 1 2006
End Date
August 1 2008
Last Update
July 25 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.